ATE277642T1 - Makromolekular träger auf basis von dextran fur arzneimittel und diagnosticum abgabe - Google Patents

Makromolekular träger auf basis von dextran fur arzneimittel und diagnosticum abgabe

Info

Publication number
ATE277642T1
ATE277642T1 AT00937555T AT00937555T ATE277642T1 AT E277642 T1 ATE277642 T1 AT E277642T1 AT 00937555 T AT00937555 T AT 00937555T AT 00937555 T AT00937555 T AT 00937555T AT E277642 T1 ATE277642 T1 AT E277642T1
Authority
AT
Austria
Prior art keywords
dextran
drug
carrier based
macromolecular carrier
diagnostic delivery
Prior art date
Application number
AT00937555T
Other languages
English (en)
Inventor
David R Vera
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE277642T1 publication Critical patent/ATE277642T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
    • A61K49/128—Linear polymers, e.g. dextran, inulin, PEG comprising multiple complex or complex-forming groups, being either part of the linear polymeric backbone or being pending groups covalently linked to the linear polymeric backbone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/50—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications
    • A61B6/508—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications for non-human patients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Pathology (AREA)
  • Dentistry (AREA)
  • Biomedical Technology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
AT00937555T 1999-05-14 2000-05-12 Makromolekular träger auf basis von dextran fur arzneimittel und diagnosticum abgabe ATE277642T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13432999P 1999-05-14 1999-05-14
PCT/US2000/013300 WO2000069473A2 (en) 1999-05-14 2000-05-12 Macromolecular carrier for drug and diagnostic agent delivery

Publications (1)

Publication Number Publication Date
ATE277642T1 true ATE277642T1 (de) 2004-10-15

Family

ID=22462862

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00937555T ATE277642T1 (de) 1999-05-14 2000-05-12 Makromolekular träger auf basis von dextran fur arzneimittel und diagnosticum abgabe

Country Status (10)

Country Link
US (1) US6409990B1 (de)
EP (1) EP1178838B1 (de)
JP (2) JP4056701B2 (de)
AT (1) ATE277642T1 (de)
AU (1) AU5270500A (de)
DE (1) DE60014359T2 (de)
ES (1) ES2228536T3 (de)
FR (1) FR15C0033I2 (de)
NL (1) NL300736I2 (de)
WO (1) WO2000069473A2 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770261B2 (en) * 1995-06-02 2004-08-03 Research Corporation Technologies Magnetic resonance imaging agents for the detection of physiological agents
JP4163381B2 (ja) 1997-11-17 2008-10-08 カリフォルニア・インスティテュート・オブ・テクノロジー 生理学的薬剤の検出のための磁気共鳴造影剤
JP4056701B2 (ja) * 1999-05-14 2008-03-05 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア 薬剤および診断薬の送達のための高分子担体
US6673333B1 (en) * 2000-05-04 2004-01-06 Research Corporation Technologies, Inc. Functional MRI agents for cancer imaging
US20040146463A1 (en) * 2000-05-04 2004-07-29 Meade Thomas J. Functional MRI agents for cancer imaging
EP1355672A2 (de) 2000-12-01 2003-10-29 Cell Works Inc. "konjugate von glykosylierten/galaktosylierten peptiden, bifunktionellen linkern und nukleotid?monomeren/polymeren, damit zusammenhängende zusammensetzungen, sowie verfahren zu ihrer verwendung"
US20030004236A1 (en) * 2001-04-20 2003-01-02 Meade Thomas J. Magnetic resonance imaging agents for detection and delivery of therapeutic agents and detection of physiological substances
WO2002087632A1 (en) * 2001-05-02 2002-11-07 Metaprobe, Inc. High throughput screening methods using magnetic resonance imaging agents
WO2003057715A2 (en) * 2001-12-28 2003-07-17 The Regents Of The University Of California Novel ligand involved in the transmigration of leukocytes .
US20030198597A1 (en) * 2002-04-22 2003-10-23 Meade Thomas J. Novel macrocyclic activatible magnetic resonance imaging contrast agents
US7651689B2 (en) * 2002-11-15 2010-01-26 Albert Einstein College Of Medicine Of Yeshiva University Methods of applying ionization radiation for therapy of infections
US20040191843A1 (en) * 2003-02-03 2004-09-30 Palo Alto Institute Of Molecular Medicine Cell-killing molecules and methods of use thereof
US7727969B2 (en) * 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
US20050171424A1 (en) * 2004-01-13 2005-08-04 The Gov. Of The Usa As Rep. By The Secretary Of The Dept. Of Health And Human Services Methods for imaging the lymphatic system using dendrimer-based contrast agents
US20050186642A1 (en) 2004-02-24 2005-08-25 Biocare Medical, Inc. Immunoassay reagents and methods of use thereof
JPWO2005117995A1 (ja) * 2004-06-03 2008-04-03 丈二 北山 ヒアルロン酸のセンチネルリンパ節同定への応用
US7381400B2 (en) * 2004-07-13 2008-06-03 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Injection of a radioactive dye for sentinel lymph node identification
US20060204443A1 (en) * 2005-03-11 2006-09-14 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Methods for tumor treatment using dendrimer conjugates
DE102005018330B4 (de) 2005-04-20 2007-04-19 Siemens Ag System zur Erzeugung von CT-Bilddatensätzen und zur Bestrahlung eines Tumor-Patienten
JP4934802B2 (ja) * 2005-05-30 2012-05-23 国立大学法人信州大学 リンパ系の細胞接着物質、リンパ系薬物輸送材およびそれを含有する薬剤
US20100272769A1 (en) * 2005-08-03 2010-10-28 Amcol International Virus-, Bacteria-, and Fungi-Interacting Layered Phyllosilicates and Methods of Use
US20070031512A1 (en) * 2005-08-03 2007-02-08 Amcol International Corporation Virus-interacting layered phyllosilicates and methods of inactivating viruses
US20080184618A1 (en) * 2005-08-03 2008-08-07 Amcol International Virus-Interacting Layered Phyllosilicates and Methods of Use
JP5563299B2 (ja) * 2006-08-17 2014-07-30 エピックス ファーマシューティカルズ，インコーポレイテッド リンパ系撮像方法
US20100196272A1 (en) * 2009-01-30 2010-08-05 Neoprobe Corporation Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran
US11077212B2 (en) 2010-08-24 2021-08-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. Molecular imaging of cancer cells in vivo
WO2012154983A2 (en) 2011-05-10 2012-11-15 Biocare Medical, Llc Systems and methods for anti-pax8 antibodies
US10316103B1 (en) 2012-03-30 2019-06-11 Biocare Medical, Llc Systems and methods for anti-Uroplakin III antibodies
EP2900265B1 (de) 2012-09-27 2018-05-30 Biocare Medical, LLC Anti-uroplakin-ii-antikörper, systeme und verfahren
US10429390B2 (en) 2012-12-18 2019-10-01 Biocare Medical, Llc Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer
ES2720483T3 (es) 2013-02-28 2019-07-22 Biocare Medical Llc Sistemas y procedimientos de anticuerpos anti p40
JP6163698B2 (ja) * 2013-03-21 2017-07-19 国立大学法人 千葉大学 マクロファージマンノース受容体を認識する新規多糖金属錯体化合物、及び、その医薬組成物
WO2015013341A1 (en) * 2013-07-22 2015-01-29 Navidea Biopharmaceuticals, Inc. Compositions, methods and kits for diagnosing and treating cd206 expressing cell-related disorders
CN104511030A (zh) * 2013-09-29 2015-04-15 复旦大学 基于葡聚糖的双模态纳米影像药物-Dex-Rho-99mTc
US9816997B2 (en) 2013-10-03 2017-11-14 Biocare Medical, Llc Anti-SOX10 antibody systems and methods
WO2015189477A1 (en) 2014-06-13 2015-12-17 Tenboron Oy Conjugates comprising an anti-egfr1 antibody
JP6722663B2 (ja) * 2014-07-17 2020-07-15 オハイオ ステート イノベーション ファウンデーション マクロファージおよび他のマンノース結合ｃ型レクチン受容体高発現細胞を標的化するための化合物および組成物、ならびにそれらを使用して治療するおよび診断する方法
US10806803B2 (en) * 2014-07-17 2020-10-20 Ohio State Innovation Foundation Compositions for targeting macrophages and other CD206 high expressing cells and methods of treating and diagnosis
CA2955441C (en) * 2014-07-17 2023-03-14 Ohio State Innovation Foundation Dextran conjugates for targeting macrophages and other cd296-expressing cells
US20180015187A1 (en) * 2015-01-21 2018-01-18 Cardinal Health 414, Llc Compounds and compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells and methods of treating and diagnosis using same
CN106317237B (zh) * 2015-07-03 2019-07-19 华中科技大学 一种用于spect成像的当归多糖衍生物及其合成方法
KR20180083304A (ko) * 2015-09-25 2018-07-20 세린, 엘엘씨 sn-117m 라벨된 만노스 결합 덱스트란 아민
US20190076557A1 (en) 2015-10-05 2019-03-14 Serene, Llc Hyaluronan sn-117m colloid for radiosynoviorthesis and symptomatic therapy related applications
EP3522938A4 (de) * 2016-10-04 2020-06-24 Cardinal Health 414, LLC Zusammensetzungen und verfahren zur diagnose und behandlung von makrophagenbedingten störungen unter verwendung eines kohlenhydratbasierten makromolekularen trägers
MX2019004029A (es) * 2016-10-07 2019-09-27 Navidea Biopharmaceuticals Inc Compuestos y metodos para diagnosis y tratamiento de infecciones virales.
JP6329302B2 (ja) * 2017-05-10 2018-05-23 国立大学法人千葉大学 マクロファージマンノース受容体を認識する新規多糖金属錯体化合物、及び、その医薬組成物
CA3151519A1 (en) * 2019-08-19 2021-02-25 Navidea Biopharmaceuticals, Inc. Compositions and related methods for the ablation of m2 macrophages and myeloid derived suppressor cells
CA3155675A1 (en) * 2019-09-30 2021-04-08 Navidea Biopharmaceuticals, Inc. Compositions and related methods for blocking off-target localization of mannosylated dextrans and other cd206 ligands
US11497763B1 (en) 2020-07-01 2022-11-15 Physis International LLC Compounds and methods for treating and diagnosing RNA virus infections
US12070504B1 (en) 2020-07-01 2024-08-27 Physis International LLC Compounds and methods for altering cyto-states of cells that express c-type lectin receptors
JP2023533405A (ja) * 2020-07-08 2023-08-03 ナビディア、バイオファーマスーティカルズ、インコーポレイテッド 均一に定められた分子量のマンノシル化デキストランおよびその誘導体の合成
EP4199936A4 (de) * 2020-08-21 2025-05-07 Resolute Science, Inc. Zusammensetzungen und verfahren zum targeting von tumorassoziierten makrophagen
US11833170B2 (en) * 2022-02-04 2023-12-05 Navidea Biopharmaceuticals, Inc. Altering net charge on mannosylated dextrans to maximize target tissue uptake and off target competitive blocking
US20230302041A1 (en) * 2022-03-25 2023-09-28 Navidea Biopharmaceuticals, Inc. Competitive Self-Blocking with Unlabeled Manocept Imaging Agents
EP4598583A2 (de) 2022-10-03 2025-08-13 Navidea Biopharmaceuticals, Inc. Amidbindungen von zuckerresten an aminterminierte leinen, die an kohlenhydratpolymeren gebunden sind

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE286598C (de)
US4707440A (en) * 1984-01-30 1987-11-17 Enzo Biochem, Inc. Nucleic acid hybridization assay and detectable molecules useful in such assay
US5175269A (en) * 1984-01-30 1992-12-29 Enzo Diagnostics, Inc. Compound and detectable molecules having an oligo- or polynucleotide with modifiable reactive group
SE465907B (sv) 1984-11-01 1991-11-18 Nyegaard & Co As Diagnosticeringsmedel innehaallande en paramagnetisk metall
US5336762A (en) * 1985-11-18 1994-08-09 Access Pharmaceuticals, Inc. Polychelating agents for image and spectral enhancement (and spectral shift)
US5490991A (en) * 1986-07-03 1996-02-13 Advanced Magnetics, Inc. Directed delivery of radioprotectants using a receptor specific carrier
US4822594A (en) 1987-01-27 1989-04-18 Gibby Wendell A Contrast enhancing agents for magnetic resonance images
CS263561B1 (en) * 1987-09-18 1989-04-14 Kery Vladimir Process for preparing water soluble allylderivatives of oligo and polysaccharides
DD286598A5 (de) * 1989-06-29 1991-01-31 Adw Der Ddr,Zi F. Mulekularbiologie,De Verfahren zur einfuehrung von primaeren aminogruppen in wasserloesliche polymere
US5789578A (en) * 1996-01-11 1998-08-04 Massey University Methods for the preparation of resins with ligands attached thereto through a linking group comprising sulfide, sulfoxide or sulfone functionality
WO1998018497A2 (en) * 1996-10-28 1998-05-07 Nycomed Imaging As Contrast agents
AU5135698A (en) * 1996-11-28 1998-06-22 Nihon Schering K.K. Contrast compound, contrast medium for mri, and method for mri
JP4056701B2 (ja) * 1999-05-14 2008-03-05 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア 薬剤および診断薬の送達のための高分子担体

Also Published As

Publication number Publication date
NL300736I1 (de) 2016-01-26
JP2007332380A (ja) 2007-12-27
EP1178838A2 (de) 2002-02-13
DE60014359T2 (de) 2006-02-23
EP1178838B1 (de) 2004-09-29
US6409990B1 (en) 2002-06-25
DE60014359D1 (de) 2004-11-04
NL300736I2 (de) 2016-01-26
FR15C0033I2 (fr) 2016-09-09
ES2228536T3 (es) 2005-04-16
FR15C0033I1 (de) 2015-06-26
JP2002544243A (ja) 2002-12-24
WO2000069473A2 (en) 2000-11-23
AU5270500A (en) 2000-12-05
JP4056701B2 (ja) 2008-03-05
WO2000069473A3 (en) 2001-08-16

Similar Documents

Publication Publication Date Title
ATE277642T1 (de) Makromolekular träger auf basis von dextran fur arzneimittel und diagnosticum abgabe
Zobi CO and CO-releasing molecules in medicinal chemistry
TR199901361T2 (xx) S�lfonamid t�revleri, haz�rlanma prosesi ve ila� olarak kullan�mlar�
ATE224888T1 (de) Pyridylalken- und pyridylalkin-säureamide als cytostatika und immunosuppressive arzneimittel
ATE327772T1 (de) Therapeutische und diagnostische ligandensysteme mit transportmolekülbindenden eigenschaften und diese enthaltende arzneimittel
DE59809588D1 (de) Arzneistoffträgerpartikel für die gewebespezifische arzneistoffapplikation
DE60038104D1 (de) Arzneimittelzubereitungen für die behandlung von alpha-galactosidase a-mangel
DE69321729D1 (de) Aminosäure-gebundene senfgas derivate und ihre verwendung als wirkstoffvorstufe in der behandlung von tumoren
TR199901949T2 (xx) Lemfositik t�m�rler i�in �areler.
DE69921138D1 (de) Arzneimittel freisetzendes system enthaltend ein homeobox-peptid und ein zytotoxisches oder antineoplastisches mittel
TR200200226T2 (tr) Karbonasitamidler, bu bileşikleri ihtiva eden ilaç, kullanımı ve üretimi.
AR004545A1 (es) Derivados de purin-6-ona, procedimientos para su preparacion, el uso de los mismos en la preparacion de medicamentos, medicamentos que los contieneny un procedimiento para preparar dichos medicamentos
ATE218142T1 (de) Nitratester von corticoid verbindungen und die therapeutische verwendungen davon
TR199802331T2 (xx) 2,4-Diaminopirimidin t�revleri.
DE69518070D1 (de) Mehrfachkomponenten-inklusionskomplexe enthaltend einen sauren arzneistoff, ein zyklodextrin und eine base
SE9702305D0 (sv) New thiazolidinedione, oxazolidinedione and oxadiazolidinedione derivatives
Rosenberg Identification of cancer antigens: impact on development of cancer immunotherapies.
Buchholz et al. Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations
TR200503846T2 (tr) Değiştirilmiş salimli ensülin sensitizörü için fterkip ve kullanımı
EP1223217A4 (de) Transporter-gene oatp-b, c, d und e
DE50306803D1 (de) Neue nickel-, palladium- und platin-carbenkomplexe, ihre herstellung und verwendung in katalytischen reaktionen
Maison et al. Improved chemical strategies for the targeted therapy of cancer
TR200302178T4 (tr) Ağrı ve alerjik reaksiyonlarla mücadele için sübstitüe edilmiş pirrol mannich bazları.
ATE402936T1 (de) Carboborane metallophthalocyanine, deren herstellung, pharmazeutische produkte und medizinische verwendungen
Heyes et al. Evaluation of 4-carbethoxy-5 (3, 3-dimethyl-1-triazeno)-2-phenylimidazole (NSC-166721) and 4-carbethoxy-5-(3, 3-dimethyl-1-triazeno)-2-methylimidazole (NSC-166722) as potential antitumor agents

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties